Adc Therapeutics SA (ADCT) — 8-K Filings

8-K Filings (17)

• 8-K Filing — May 4, 2026
• 8-K Filing — Dec 5, 2025
• ADC Therapeutics SA Files 8-K: Material Agreement & Financials — Oct 14, 2025 Risk: medium
  ADC Therapeutics SA announced on October 12, 2025, that it has entered into a material definitive agreement. The company also reported on its results of operati
• ADC Therapeutics SA Files 8-K on Sept 30, 2025 — Sep 30, 2025 Risk: low
  ADC Therapeutics SA filed an 8-K on September 30, 2025, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The filing d
• ADC Therapeutics SA Files 8-K: Material Agreement, Costs, Equity Sales — Jun 12, 2025 Risk: medium
  ADC Therapeutics SA announced on June 11, 2025, that it has entered into a material definitive agreement. The company also reported on costs associated with exi
• ADC Therapeutics SA Files 8-K — Jun 5, 2025 Risk: low
  ADC Therapeutics SA filed an 8-K on June 3, 2025, to report on matters submitted to a vote of security holders and to file financial statements and exhibits. Th
• ADC Therapeutics SA Files 8-K on Financials — Jan 13, 2025 Risk: low
  ADC Therapeutics SA filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD dis
• ADC Therapeutics SA Files 8-K on Shareholder Votes & Financials — Nov 13, 2024 Risk: low
  ADC Therapeutics SA filed an 8-K on November 13, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing date fo
• ADC Therapeutics Sells Zynlonta Royalty Rights for $100M — Jun 14, 2024 Risk: medium
  ADC Therapeutics SA announced on June 13, 2024, that it has entered into a definitive agreement to sell its royalty rights for Zynlonta to an affiliate of Monta
• ADC Therapeutics Sells Royalty Rights for $50M, Raises $100.1M — May 14, 2024 Risk: medium
  ADC Therapeutics SA announced on May 14, 2024, that it has entered into a definitive agreement to sell its royalty rights for Zynlonta (loncastuximab tesirine-l
• ADC Therapeutics Sells Zynlonta Royalty Rights for $50M — May 8, 2024 Risk: medium
  ADC Therapeutics SA announced on May 6, 2024, that it has entered into a definitive agreement to sell its royalty rights for Zynlonta (loncastuximab tesirine-lp
• ADC Therapeutics Sells Zynlonta Royalty Rights for $100M — Apr 9, 2024 Risk: medium
  ADC Therapeutics SA announced on April 9, 2024, that it has entered into a definitive agreement to sell its royalty rights for Zynlonta to an affiliate of Lyell
• ADC Therapeutics Sells Zynlonta Royalty Rights for $50M — Mar 5, 2024 Risk: medium
  ADC Therapeutics SA announced on March 5, 2024, that it has entered into a definitive agreement to sell its royalty rights for Zynlonta (loncastuximab tesirine-
• ADC Therapeutics Reports Officer Changes and Compensation Arrangements — Feb 29, 2024 Risk: medium
  ADC Therapeutics SA filed an 8-K on February 29, 2024, reporting events from February 23, 2024. The filing pertains to the departure of directors or certain off
• ADC Therapeutics Enters Material Definitive Agreement on Jan 18 — Jan 24, 2024
  ADC Therapeutics SA filed an 8-K on January 24, 2024, reporting a material definitive agreement entered into on January 18, 2024. This filing indicates a signif
• ADC Therapeutics Reports Undisclosed Material Agreement — Jan 19, 2024
  ADC Therapeutics SA filed an 8-K on January 19, 2024, reporting an "Entry into a Material Definitive Agreement" that occurred on January 16, 2024. While the fil
• ADC Therapeutics to Present at J.P. Morgan Healthcare Conference Jan 8 — Jan 4, 2024
  ADC Therapeutics SA filed an 8-K on January 4, 2024, to announce that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, a

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX